Industry

In the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile Approval was also based on data from the Phase 2 PILOT study, the first and only company-sponsored study of a CAR … [Read more…]

ARCADIA, Calif.–(BUSINESS WIRE)–Global entrepreneur and Arcadia resident Charles Huang, PhD, has announced he will donate $7.5 million to Methodist Hospital which will be the largest single gift in the 119-year history of the hospital. Media Invited:   Signing Ceremony for Largest-Ever Single Gift to Methodist Hospital Date & Time:   Monday, June 27 at 11:30 … [Read more…]

Dr. Christine Olsen transitions to executive chair of the organization’s board of directors CAMBRIDGE, Mass.–(BUSINESS WIRE)–The Food Allergy Science Initiative (FASI) today named veteran healthcare research leader John Walter as CEO of the food allergy research organization. Walter had served as chief operating officer for FASI since January of this year. Walter is the former … [Read more…]

LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding the Company’s request for an immediate suspension of trading in the Company’s ordinary shares on AIM … [Read more…]

HALIFAX, Nova Scotia–(BUSINESS WIRE)–CUPE support staff who work in long-term care, their co-workers, and friends, will hold rallies across the province as part of a “Day of Action” on Monday, June 27, calling on the government to increase wages for support staff too. Rallies will take place across the province from 11 am to 1 … [Read more…]

Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the … [Read more…]

Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5% improved and 34.1% preserved) at Month 48 of the DAYBREAK open-label extension trial Zeposia was well tolerated, with more than 80% of people staying … [Read more…]

Analysis of ongoing DAYBREAK open-label extension trial of Zeposia showed that seroconversion occurred in 100% of those treated with mRNA vaccines and in a majority of those treated with non-mRNA vaccines New analyses to be featured in late-breaking research session at the 8th European Academy of Neurology Congress in Vienna, Austria Data are among five … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering. Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast to 2028″ gives comprehensive insights on the various Lu-177 based drugs being developed for the treatment of prostate cancer, NETs, Lung cancer, solid tumors and other … [Read more…]

— Data being presented at the European Academy of Neurology Congress demonstrates consistent reductions in NMOSD attacks and disability scores across populations — DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced new findings from a post hoc analysis of the N-MOmentum Phase 3 pivotal trial of UPLIZNA supporting the medicine’s efficacy in Europeans living with … [Read more…]